| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/01/1999 | WO1999015194A1 Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 04/01/1999 | WO1999015191A2 Cytokines having neurotrophic activity |
| 04/01/1999 | WO1999015186A1 Cationic polymers as toxin-binding agents |
| 04/01/1999 | WO1999015170A1 Vitronectin receptor antagonist |
| 04/01/1999 | WO1999015169A1 Thrombin inhibitors |
| 04/01/1999 | WO1999015166A1 Parasiticidal formulations |
| 04/01/1999 | WO1999015164A1 Amide derivatives for the treatment of diseases mediated by cytokines |
| 04/01/1999 | WO1999015163A1 Treatment of conduct disorder |
| 04/01/1999 | WO1999015160A2 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 04/01/1999 | WO1999014998A2 Method for preventing and treating hearing loss using sensorineurotrophic compounds |
| 04/01/1999 | WO1999003878A3 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis |
| 04/01/1999 | WO1999003826A3 Metalloproteinase inhibitors |
| 04/01/1999 | WO1999002497A3 Pyridine derivatives |
| 04/01/1999 | WO1999001117A3 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins |
| 04/01/1999 | WO1998056370A3 Therapeutic nanospheres |
| 04/01/1999 | WO1998055615A9 Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 04/01/1999 | WO1998054313A3 Dna methyltransferase genomic sequences and antisense oligonucleotides |
| 04/01/1999 | WO1998053856A9 Methods for the detection, treatment, and prevention of neurodegeneration |
| 04/01/1999 | WO1998052573A9 Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| 04/01/1999 | WO1998051787A3 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
| 04/01/1999 | WO1998051321A9 Tissue factor for influencing blood vessel formation |
| 04/01/1999 | WO1998048785A3 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 04/01/1999 | WO1998039464A8 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| 04/01/1999 | WO1998014592A3 Telomerase reverse transcriptase |
| 04/01/1999 | DE19741955A1 Mittel gegen bakterielle Meningitis Medicines for bacterial meningitis |
| 04/01/1999 | CA2304849A1 Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 04/01/1999 | CA2304783A1 Method of identification of leads or active compounds |
| 04/01/1999 | CA2304647A1 Method for preventing and treating hearing loss using sensorineurotophic compounds |
| 04/01/1999 | CA2304615A1 Agents for combating bacterial meningitis |
| 04/01/1999 | CA2304397A1 Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them |
| 04/01/1999 | CA2304283A1 Parasiticidal formulations |
| 04/01/1999 | CA2304138A1 Benzothiophenes |
| 04/01/1999 | CA2304129A1 Tie ligand homologues |
| 04/01/1999 | CA2303994A1 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives |
| 04/01/1999 | CA2303918A1 Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 04/01/1999 | CA2303883A1 C3a receptor ligands |
| 04/01/1999 | CA2303846A1 Vitronectin receptor antagonist |
| 04/01/1999 | CA2303487A1 Vitronectin receptor antagonists |
| 04/01/1999 | CA2303359A1 1,5-diphenylpyrazole derivatives |
| 04/01/1999 | CA2302572A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 04/01/1999 | CA2301957A1 Antisense oligonucleotides against thymidylate synthase |
| 04/01/1999 | CA2301693A1 Cytokines having neurotrophic activity |
| 04/01/1999 | CA2301614A1 Thrombin inhibitors |
| 04/01/1999 | CA2300051A1 Amide derivatives for the treatment of diseases mediated by cytokines |
| 04/01/1999 | CA2272605A1 Pharmaceutical composition containing gp34 binding-inhibitory agent as effective ingredient |
| 03/31/1999 | EP0905512A1 Method of identification of leads or active compounds |
| 03/31/1999 | EP0905253A2 Adenoviral vector deleted of all E4-ORF except ORF6 |
| 03/31/1999 | EP0905245A1 Staphylococcal polypeptides Spo0J1 |
| 03/31/1999 | EP0905238A2 Pigrl-1, a member of immunoglobin gene superfamily |
| 03/31/1999 | EP0905233A2 Staphylococcus aureus trigger factor |
| 03/31/1999 | EP0905132A1 Benzothiophenes |
| 03/31/1999 | EP0905126A1 Metalloproteinase inhibitors |
| 03/31/1999 | EP0904384A2 Tyrosine-phosphatase-related protein |
| 03/31/1999 | EP0904373A1 Targeted delivery of genes encoding interferon |
| 03/31/1999 | EP0904366A1 Apo-2li and apo-3 apoptosis polypeptides |
| 03/31/1999 | EP0904287A2 Cytokine designated lerk-8 |
| 03/31/1999 | EP0904274A1 Farnesyl transferase inhibitors |
| 03/31/1999 | EP0904269A1 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| 03/31/1999 | EP0904260A1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids |
| 03/31/1999 | EP0904110A1 Nitric oxide donors capable of reducing toxicity from drugs |
| 03/31/1999 | EP0904108A1 METHODS FOR TREATMENT OF ALLERGIC DISEASES WITH IgE |
| 03/31/1999 | EP0904107A1 Immunoglobin-like domains with increased half lives |
| 03/31/1999 | EP0904090A1 Egg anti-inflammatory composition, method of isolation and use |
| 03/31/1999 | EP0904085A1 USE OF ESTROGEN TO MODIFY THE AMOUNT OF SEROTONIN TRANSPORTER OR ITS mRNA |
| 03/31/1999 | EP0904080A1 Inhibitors of farnesyl-protein transferase |
| 03/31/1999 | EP0904076A1 Inhibitors of farnesyl-protein transferase |
| 03/31/1999 | EP0904073A1 Zwitterionic compositions and methods as biological response modifiers |
| 03/31/1999 | EP0904069A1 Pla2 inhibitors of angiogenesis |
| 03/31/1999 | EP0762886A4 Icam-1/lfa-1 short-chain peptides and method of using same |
| 03/31/1999 | EP0750507A4 PROTEASOME REGULATION OF NF--g(k)B ACTIVITY |
| 03/31/1999 | EP0733035B1 Tricyclic derivatives, pharmaceutical compositions containing them |
| 03/31/1999 | EP0660711B1 Novel use of inhibitors of phosphodiestersase iv |
| 03/31/1999 | EP0591378B1 Method of preventing and treating chemotherapy-induced alopecia |
| 03/31/1999 | EP0591275B1 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions |
| 03/31/1999 | CN1212696A Pyrimido [5,4-d] pyrimidines, medicaments containing these componds, their use and process for their production |
| 03/31/1999 | CN1212695A 4-amino pyrimidine derivates, medicament containing these compounds, their use |
| 03/31/1999 | CN1212694A Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production |
| 03/31/1999 | CN1212692A Substituted A2a-and diazacycloheptane and cyclooctane compounds and their use |
| 03/31/1999 | CN1212691A Tricyclic compound and its preparation and use |
| 03/31/1999 | CN1212689A Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds |
| 03/31/1999 | CN1212684A 4-anilinoquinazoline derivatives |
| 03/31/1999 | CN1212628A Method of promoting bone growth with hyaluronic acid and growth factors |
| 03/31/1999 | CN1212622A Use of antagnoist of PPAR-alpha and PPAR-gamma for treatment of syndrom X |
| 03/31/1999 | CN1212620A Mercapto derivatives as inhibitors of cyclooxygenases |
| 03/31/1999 | CN1212255A Biphenylsulfonyl cyanamides, process for their preparation, and their use as medicament |
| 03/31/1999 | CN1212160A Baoyuan Fuchun Yunqi plaster |
| 03/31/1999 | CN1042730C Method for preparing pyrazolopyridine compound |
| 03/30/1999 | US5889143 Evaluation and treatment of patients with progressive immunosuppression |
| 03/30/1999 | US5889056 Of nitric oxide synthase; hypotensive agent, antiinflammatory agents, antiarthritic agents |
| 03/30/1999 | US5889053 Anticarcinogenic agents |
| 03/30/1999 | US5889049 Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators |
| 03/30/1999 | US5889042 Method of treating diseases and conditions with estrogen agonists and antagonists |
| 03/30/1999 | US5889037 Prevention, therapy tissue damage from lipid peroxidation |
| 03/30/1999 | US5889026 N-methyl-d-asparatate-receptor subtype selective blocker |
| 03/30/1999 | US5889024 Substituted heterocycles |
| 03/30/1999 | US5889014 Heterocyclic compounds for inhibiting phosphodiesterase IV |
| 03/30/1999 | US5889008 Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives |
| 03/30/1999 | US5889003 Phosphodiesterase inhibitor |
| 03/30/1999 | US5889002 Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| 03/30/1999 | US5888994 Anticancer agnets; antitumor agents; glandular disorders |